Evaluating of the Impact of a Connected and Non-intrusive Device in Improving the Screening of Sleep Apnea Syndrome and the Addressing of Potentially Pathological Patients in Hospital Environment — AMELIAS  

Diabetes Clinical Trial

Official title: Evaluating of the Impact of a Connected and Non-intrusive Device in Improving the Screening of Sleep Apnea Syndrome and the Addressing of Potentially Pathological Patients in Hospital Environment

Status Recruiting

Clinical Trial Summary

Diabetes, obesity and metabolic syndrome are closely linked to sleep apnea syndrome. Indeed, diabetic and/or obese patients present an increased risk of sleep apnoea syndrome (SAS), with a prevalence estimated at between 10 and 22%, depending on the study, and most of them requiring treatment with Continuous Positive Airway Pressure (CPAP). In this sub-population of patients, only between 40% and 50% benefit from CPAP.

Clinical Trial Description

There is therefore an under-referral of diabetic patients to treatment, perhaps linked to the way care is organized, which clogs up the circuit and slows down or even prevents access to care. The investigators would like to test a new organization of care to facilitate and intensify this screening. ;

Related Conditions & MeSH terms

• Apnea
• Diabetes
• Metabolic Syndrome
• Obese
• Sleep Apnea Syndromes
• Syndrome

• NCT number: NCT06141967
• Study type: Interventional
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: Natacha GERMAIN, MD PhD
• Phone: (0)477120621
• Email: natacha.germain@chu-st-etienne.fr
• Status: Recruiting
• Phase: N/A
• Start date: November 30, 2023
• Completion date: September 2025